摘要
急性髓系白血病(AML)是一种高度异质性的恶性血液病,临床治疗以传统化疗为主,但疗效有限,也有部分患者因体能状态差和伴随疾病而不能接受化疗。基因改变在AML的诊断和预后判断中起重要的作用,也为分子靶向治疗提供了靶点;同时,免疫治疗在AML患者中取得了一定的疗效,具有较好的应用前景。
Acute myelogenous leukemia(AML)is a highly heterogeneous malignant hematologic disease,and it is mainly treated with traditional chemotherapy,but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy.Gene changes play an important role in the diagnosis and prognosis of AML,and these gene changes also provide targets for molecular targeted therapy.Meanwhlie,immunotherapy has achieved certain curative effects in AML and has a promising prospect.In this review,targeted therapy and immunotherapy of AML reported in 61st American Society of Hematology(ASH)Annual Meeting are summarized.
作者
米瑞华
陈琳
魏旭东
Mi Ruihua;Chen Lin;Wei Xudong(Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China)
出处
《白血病．淋巴瘤》
CAS
2020年第1期9-16,共8页
Journal of Leukemia & Lymphoma
基金
河南省医学科技攻关计划省部共建项目(201701027)。
关键词
白血病
髓样
急性
免疫疗法
基因改变
分子靶向治疗
Leukemia
myelogenous
acute
Immunotherapy
Gene change
Molecular targeted therapy
